Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Loblaw

Showing results (1-10 of 274) with videos related to

Pageof 28
Sort By:
The Lancet. Oncology|March 4, 2014
The value of randomised trials for prostate cancer managementAndrew Loblaw
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 2, 2016
Is it time to end lone-wolf medicine?Andrew Loblaw
Cancer Journal (Sudbury, Mass.)|January 25, 2020
Stereotactic Ablative Body Radiotherapy for Intermediate- or High-Risk Prostate CancerAndrew Loblaw
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 19, 2012
Opportunity lost and found: Any easy way to improve outcomes for prostate cancer patients in the postoperative setting?D Andrew Loblaw
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 6, 2012
Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con positionD Andrew Loblaw
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 16, 2011
A new dawn in prostate cancer management: Do we have the trials to support it?D Andrew Loblaw
Canadian Family Physician Medecin De Famille Canadien|July 1, 2005
Vitamin E might increase risk of deathMichael Lock, Andrew Loblaw
Current Opinion in Supportive and Palliative Care|July 5, 2011
Malignant extradural spinal cord compression in men with prostate cancerAndrew Loblaw, Gunita Mitera
Lancet (London, England)|November 23, 2024
Prostate radiotherapy in the era of intensified systemic treatment of metastatic prostate cancerCristian Udovicich, Andrew Loblaw
Future Oncology (London, England)|March 12, 2015
Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future directionH Bindu Musunuru, Andrew Loblaw
Pageof 28

Showing results (1-10 of 274) with videos related to

Sort By:
Pageof 28
The Lancet. Oncology|March 4, 2014
The value of randomised trials for prostate cancer managementAndrew Loblaw
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|November 2, 2016
Is it time to end lone-wolf medicine?Andrew Loblaw
Cancer Journal (Sudbury, Mass.)|January 25, 2020
Stereotactic Ablative Body Radiotherapy for Intermediate- or High-Risk Prostate CancerAndrew Loblaw
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 19, 2012
Opportunity lost and found: Any easy way to improve outcomes for prostate cancer patients in the postoperative setting?D Andrew Loblaw
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 6, 2012
Be it resolved that in the modern era, the best method for dose escalation is brachytherapy: The con positionD Andrew Loblaw
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|June 16, 2011
A new dawn in prostate cancer management: Do we have the trials to support it?D Andrew Loblaw
Canadian Family Physician Medecin De Famille Canadien|July 1, 2005
Vitamin E might increase risk of deathMichael Lock, Andrew Loblaw
Current Opinion in Supportive and Palliative Care|July 5, 2011
Malignant extradural spinal cord compression in men with prostate cancerAndrew Loblaw, Gunita Mitera
Lancet (London, England)|November 23, 2024
Prostate radiotherapy in the era of intensified systemic treatment of metastatic prostate cancerCristian Udovicich, Andrew Loblaw
Future Oncology (London, England)|March 12, 2015
Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future directionH Bindu Musunuru, Andrew Loblaw
Pageof 28